Post-infectious inflammatory syndrome associated with SARS-CoV-2 in a paediatric patient with Down syndrome

Mellad Khoshnood 1, Roshan Mahabir, Nick M Shillingford, Jonathan D Santoro

SUMMARY
Neurological complications of SARS-CoV-2 continue to be recognised. In children, neurological phenomenon has been reported generally in the acute infectious period. It is possible that SARS-CoV-2 could trigger an immunemediated post-infectious phenomenon. Here, we present a unique case of post-infectious marantic cardiac lesion causing cerebrovascular accident in a patient with Down syndrome.

BACKGROUND
Down syndrome (DS) is a well-described genetic disorder typically associated with trisomy of chromosome 21, with a prevalence of 1 in 600 live births in the USA.1 Persons with DS are known to have immune dysregulation, which most frequently manifests as increased risk of infections and inadequate vaccine responses.1 2 Although there are emerging data on the impact of primary infection with SARS-CoV-2 in this population,3 no reports of post-infectious phenomenon, nor cerebrovascular disease, have been reported in children with DS.

SARS-CoV-2 has been reported in the USA for over 7 months, yet limited data have emerged on late post-infectious phenomenon in children. Multi-system inflammatory syndrome in children (MIS-C) has emerged as a recognised concept regarding the early post-infectious ramifications of SARS-CoV-2 infection in paediatric patients, producing a more severe Kawasaki syndrome-like presentation.4 This literature has not identified neurological sequelae from MIS-C, matching early data out of China indicating low rates of neurological complications.4

The role of SARS-CoV-2 in the early activation of the inflammatory cascade has provided a construct to evaluate cerebrovascular disease in adults.5 6 There are reports regarding primary SARS-CoV-2 infection producing hypercoagulable states and cerebrovascular accidents (CVAs) in otherwise healthy adults with an estimated risk of 0.5%, although the exact aetiology remains unclear and likely heterogeneous.5 6 Here, we report the first case of potential SARS-CoV-2-related CVA in a paediatric patient and the first description of a post-infectious inflammatory cardiac lesion in a child.

CASE PRESENTATION
A 3-year-old girl with Down syndrome (DS), unbalanced atrioventricular (AV) canal status post a 1.5 ventricle repair, a Glenn shunt, atrial septal defect (ASD)/ventricular septal defect (VSD) patch, venovenous collateral ligation resulting in four-chamber physiology with hypoplastic right ventricle, pulmonary hypertension and obstructive sleep apnoea with a recent primary infection with SARS-CoV-2 3 months prior presented to the hospital with recurrent fever of unknown origin. In her initial visit to the emergency department, she underwent a broad infectious workup which was negative, including SARS-CoV-2 nasopharyngeal PCR, but had presence of SARS-CoV-2 immunoglobulin G (IgG) antibodies (titre: 6.1, reference range <0.7). She was subsequently discharged because of improved oral intake and no identifiable pathology to warrant admission; however, she returned the following week with new onset dysarthria, with wide-spaced gait and falling.

Her examination was remarkable for wide-based gait, irritability, dysarthria and diminished expressive language. She had no other localising findings including nystagmus, dysmetria or titubation while sitting. She subsequently developed rigours associated with hyperthermia and with significant and persistent episodes of desaturations and cyanosis. Notably, the patient’s fevers were responsive to antipyretic interventions, improving her irritability, rigours and frequency of desaturations with administration. Given high antibody titres in the setting of concern for cardiac dysfunction, a presumptive diagnosis of multisystem inflammatory syndrome in children (MIS-C) was made even though SARS-CoV-2 PCR was negative. The patient continued to have tachycardia with wide heart rate variability and pulse pressures, but had few other overt features of MIS-C.

INVESTIGATIONS
Serum and cerebrospinal fluid (CSF) findings are reported in table 1 but were notable for pancytopenia and elevated inflammatory biomarkers. Once clinically stable, neuroimaging was obtained with an MRI of the brain which was remarkable for multiple areas of embolic infarct without surrounding oedema in addition to an area of haemorrhage within the left cerebellar hemisphere (figure 1). There was low suspicion that these were septic emboli given lack of inflammatory changes around the areas of infarct, which primarily seeded the grey/white junctions. This prompted a cardiac investigation with an echocardiogram...
Case report

demonstrating a large thrombus identified along the length of her ASD patch, extending across the plane of the AV valve and along the VSD patch with protrusions into the ventricle via the mitral valve. She had an echocardiogram obtained 2 months prior as an outpatient that was noted to be stable.

TREATMENT

As the patient’s prior cardiac surgeries were deemed high risk for the sedation for an MRI, she was administered empiric intravenous immunoglobulin (IVIg) of 2 g/kg over 2 days and 3 days of intravenous methylprednisolone (30 mg/kg/day). She was also on empiric ceftriaxone, but after 48 hours of culture negative status, this was discontinued. The patient had improvement of her mental status, mood and balance within 5 days of completion of IVIg. Additionally, she engaged more with providers, spoke more, although with notable dysarthria, and had more symmetric movement of her extremities with generally improved truncal stability. Further, her C-reactive protein (CRP) was downtrending, which is further detailed in figure 2.

After consideration of risks and benefits of intervention, it was decided to attempt to remove the thrombus, given significant risk for occlusion or further thromboembolism. The patient tolerated the procedure well and it was notable that the patient had subsequent improvement of inflammatory biomarkers. The pathology service received a 2.8×1.9×0.9 cm specimen designated intra-atrial septal patch inflammatory tissue. Grossly, cut sections of the specimen revealed a tan-pink to white cut surface with focal areas of possible purulent exudate. Representative sections are submitted for microscopic examination. Histological sections revealed endomyocardial tissue and patch material involved by both acute and chronic inflammation. The areas of chronic inflammation are characterised by dense fibrotic tissue with a florid chronic inflammatory infiltrate composed of a predominance of plasma cells and mature lymphocytes and only occasional neutrophils (figure 3A,B). Granulation tissue formation is

| Table 1 | Clinical data |
| --- | --- | --- |
| **Laboratory test** | **Patient** | **Reference value** |
| Serum TSH | 2.07 ng/dL | 0.5–5.0 ng/dL |
| Free T4 | 1.63 ng/dL | 0.96–1.72 ng/dL |
| CRP (max) | 15.5 mg/dL | 0.0–0.9 mg/dL |
| ESR (max) | 20 mm/hour | 1–10 mm/hour |
| Complement C3 | 104 mg/dL | 80–178 mg/dL |
| Complement C4 | 16 mg/dL | 13–47 mg/dL |
| Antinuclear antibody | Negative | Negative |
| DNase-B antibody | 151 U/L | Negative |
| Proteinase 3 antibody | 0.2 | <0.4 |
| Myeloperoxidase antibody | <0.2 | <0.4 |
| Cardiolipin IgA | 22 U/L | <13.9 U/L |
| Cardiolipin IgG | 70 U/L | <9.9 U/L |
| Cardiolipin IgM | 1.5 U/L | <9.9 U/L |
| Toxoplasma IgM/IgG | Negative | Negative |
| Rickettsia IgM/IgG | Negative | Negative |
| QuantIFERON | Negative | Negative |
| Brucellosis IgM/IgG | Negative | Negative |
| Legionella IgA/IgG | Negative | Negative |
| Q Fever IgM/IgG Phase 1/2 | Negative | Negative |
| **Cerebrospinal fluid** | | |
| WCC | 31 cells/mm³ | <5 cells/mm³ |
| RCC | 28,000 cells/mm³ | 0 cell/mm³ |
| % lymphocytes | 9% | 30%–90% |
| Glucose | 38 mg/dL | 37–75 mg/dL |
| Protein | 110 mg/dL | 15–60 mg/dL |
| Oligoclonal bands | Negative | Negative |
| IgG index | 1.15 | <0.60 |
| Neopterin | 93 nmol/L | 7–65 nmol/L |
| Infectious PCR panel | Negative | Negative |
| Culture negative | Negative | Negative |
| Gram stain | Negative | Negative |
| Paraneoplastic/encephalitis panel (Mayo) | Negative | Negative |

CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; Ig, immunoglobulin; TSH, thyroid stimulating hormone.
also appreciated. The acutely inflamed areas are characterised by a vegetative growth of predominantly necrotic tissue associated with a purulent exudate composed of aggregates of neutrophils admixed with fibrinopurulent material (figure 3C). Several detached fragments of fibrinopurulent exudates contain clusters of neutrophils and associated fibrinoid material (figure 3D). Gram, GMS (grocotts methenamine (Gomori) silver) and periodic acid-Schiff (PAS) stains failed to demonstrate bacterial forms or fungi.

OUTCOME AND FOLLOW-UP
Our patient tolerated her procedures and after close clinical monitoring after cardiac intervention, she was deemed stable for discharge home to continue a full course of antibiotics for presumed bacterial endocarditis. She is clinically continuing to improve but is noted for difficulty with gait towards the latter half of the day/evening, but continues to work with both physical therapy and occupational therapy. Her speech is continuing to improve with engagement with speech therapy. She has had no recurrence of disease.

DISCUSSION
To our knowledge, this is the first report of a SARS-CoV-2 post-infectious inflammatory phenomenon in a child with unique features of inflammatory endocarditis and CVA complicating the case. This report is even more dramatic in the context of occurring in a child with DS, a population prone to both cardiac disease and immune dysregulation, raising the possibility that this phenomenon could be observed in other children with either DS and/or prior abnormal cardiovascular structural physiology.

The patient had evidence of systemic inflammation, although the pathology observed in her heart was felt to be a prominent driver of disease. This inflammatory vegetative lesion, on pathological evaluation, was most similar to a Libman-Sacks endocarditis (LSE) as observed in persons with systemic lupus erythematosus or other autoimmune conditions that produce immune dysregulation. Classic LSE is characterised by sterile accumulation of platelets and fibrin tissue within the endocardium, generally involving cardiac valves that can produce valvular insufficiency. These lesions are prone to secondary infection as well as embolisation, which was felt to be the aetiology of this patient’s CVA. Although there has not been a significant correlation with LSE in persons with DS, such patients are known to have immune dysregulation which could potentially place them at risk for marantic cardiac lesions under unique circumstances. The patient’s inflammatory evaluation was notable only for elevations in non-specific biomarkers such as ESR and CRP, although the patient was noted to have low titre anticardiolipin antibodies (immunoglobulin A (IgA) and IgG). While this was not felt to be the primary aetiology of the patient’s clinical presentation, especially in the setting of a negative anti-nuclear antibody (ANA) and double stranded DNA antibody (dsDNA), it was felt that these biomarkers may have represented the patient’s inflammatory state. Of note, our patient had a normal echocardiogram 2 months prior to her hospitalisation, making an infectious or inflammatory endocarditis associated with primary SARS-CoV-2 infection significantly less likely. This is of particular relevance given the frequency of congenital cardiac disease necessitating repair in children with DS.

The role of immune dysregulation associated with DS is unclear in this case. It is well known and understood that patients with trisomy of chromosome 21 have immune dysregulation. This may either present itself as an increased susceptibility to infectious processes, such as frequent ear infection and upper respiratory infections, or produce autoimmune disorders, such as Hashimoto’s thyroiditis, type I diabetes and coeliac disease. Whether or not this predisposition towards infection may have lowered the threshold for primary infection with SARS-CoV-2 or post-infectious inflammatory phenomenon is unknown as there is no single clinical biomarker to prove this hypothesis.

In this patient, the suspicion was further increased given her dramatic improvement of symptoms after being administered immunomodulatory therapies via IVIg and intravenous methylprednisolone. Further, the lack of any infectious aetiology being identified in blood, CSF or on pathological examination further drives down the primary infection hypothesis.
Learning points

► Children with Down syndrome (DS) are known to have immune dysregulation and a predilection for autoimmune disease, potentially increasing the risk for the development of post-infectious autoimmune phenomenon following primary infection with SARS-CoV-2.

► Very high rates of congenital heart disease in children with DS creates potential nidus for cardiac vegetations and may create a particularly susceptible location for marantic lesions following infection with SARS-CoV-2.

► In children with DS with unexplained fevers and inflammatory labs, detailed examination of the cardiac system is highly suggested.

Provenance and peer review  Not commissioned; externally peer reviewed.

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

ORCID iD
Mellad Khoshnoud http://orcid.org/0000-0003-2232-8341

REFERENCES

1. Ram G, Chien J. Infections and immunodeficiency in Down syndrome. Clin Exp Immunol 2011;164:9–16.
2. Kusters MAA, Verstegen RHL, Gemen EFA, et al. Intrinsic defect of the immune system in children with Down syndrome: a review. Clin Exp Immunol Med 2009;156:189–93.
3. Krishnan US, Krishnan SS, Jain S, et al. SARS-CoV-2 infection in patients with Down syndrome, congenital heart disease, and pulmonary hypertension: Is Down syndrome a risk factor? J Pediatr 2020;225:246–8.
4. Abrams JY, Godfrey-Cato SE, Oster ME, et al. Multisystem Inflammatory Syndrome in Children Associated with Severe Acute Respiratory Syndrome Coronavirus 2: A Systematic Review. J Pediatr 2020;226:45–54.
5. Divani AA, Andalib S, Di Napoli M, et al. Coronavirus disease 2019 and stroke: clinical manifestations and pathophysiological insights. J Stroke Cerebrovasc Dis 2020;29:104941.
6. Morassi M, Bagatto D, Cobelli M, et al. Stroke in patients with SARS-CoV-2 infection: case series. J Neurol 2020;267:2185–92.
7. Versacci P, Di Carlo D, Dilligio MC, et al. Cardiovascular disease in Down syndrome. Curr Opin Pediatr 2018;30:616–22.
8. Zhang Y, Che M, Yuan J, et al. Aberrations in circulating inflammatory cytokine levels in patients with Down syndrome: a meta-analysis. Oncotarget 2017;8:84489–96.
9. Bloemens BLP, Broers CJM, Bont L, et al. Increased risk of respiratory tract infections in children with Down syndrome: the consequence of an altered immune system. Microbes Infect 2010;12:799–808.
10. Carsetti R, Valentinii D, Marcellini V, et al. Reduced numbers of switched memory B cells with high terminal differentiation potential in Down syndrome. Eur J Immunol 2015;45:963–14.
11. Lee AL, Nagawa SM, Cheema GS, et al. Revisiting Libman-Sacks endocarditis: a historical review and update. Clin Rev Allergy Immunol 2009;36:126–30.
12. Goldacre MJ, Watt CJ, Seagroatt V, et al. Anticardiolipin antibodies and myocarditis in children with Down syndrome: a record linkage study. Arch Dis Child 1998;73:160–3.
13. Jap K, Viscardi MR, Marcus AI, et al. Cardiovascular disease in Down syndrome. Eur J Cardiovasc Dis 2020;286:198043.
14. Sacks endocarditis: a historical review and update. Clin Rev Allergy Immunol 2009;36:126–30.
15. Aversa T, Valenzise M, Salerno M, et al. Metamorphic thyroid autoimmunity in Down syndrome: from Hashimoto’s thyroiditis to Graves’ disease and beyond. Ital J Pediatr 2015;41:87.
16. Anwar AI, Walker JD, Frier BM. Type I diabetes mellitus and Down’s syndrome: prevalence, management and diabetic complications. Diabet Med 1998;15:160–3.
17. Carlsson A, Axelson I, Borull S, et al. Prevalence of IgA-antigliadin antibodies and IgA-antendomysium antibodies related to celiac disease in children with Down syndrome. Pediatrics 1998;101:272–5.
18. Li J, Gong X, Wang Z, et al. Clinical features of familial clustering in patients infected with 2019 novel coronavirus in Wuhan, China. Virus Res 2020;286:198043.
19. Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020;46:846–8.
20. Balachandar V, Mahalaxmi I, Subramaniam M, et al. Follow-up studies in COVID-19 recovered patients - is it mandatory? Sci Total Environ 2020;729:139021.
21. Conte WL. Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia. Mult Scler Relat Disord 2020;44:102315.
22. Montalvan V, Lee J, Bueso T, et al. Neurolological manifestations of COVID-19 and other coronavirus infections: a systematic review. Clin Neurol Neurosurg 2020;194:105921.
23. Jack D, Noitling A, Galazka A. Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets. Mult Scler Relat Disord 2020;46:102469.

Contributors  The authors listed herein all contributed in a significant way to the creation and submission of this article. MK and JDS identified the case of interest. MK created the initial draft. JDS, MK, RM and NK edited the draft. MK, JDS, RM and NK made further edits and alterations of the draft. RM and NK gathered substantial data, images and information regarding the pathology slides noted above. MK and JDS obtained and reviewed the laboratory values noted above. All authors discussed the findings and contributed to the final manuscript. All authors approved the final draft of this paper.

Funding  The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests  None declared.

Patient consent for publication  Parental/guardian consent obtained.
